Who we are
Medicines for Europe
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast
Newsroom
Press releases
In the news
Press kit
Contact us
Login
Generic medicines
Home
Who we are
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Who we are
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Environment of value added medicines in Europe
Definition
THERAPEUTIC AREAS
Q&A
What’s new
Environment of value added medicines in Europe
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Value Added Medicines award 2019
QUOTES
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Newsroom
Filters:
Value added medicines
x
in-the-news
x
2017
x
News about
By type
In the news
Press releases
By year
2022
2021
2020
2019
2018
2017
2016
2015
2014
Twitter
Tweets
Videos
Photos
Value-added medicines: how repurposed medicines bring value to patients and pharmacists
21 December 2017
Open
Manufacturing cost transparency could combat pricing criticism, says expert
2 November 2017
Open
Europe needs change to drive added value
15 September 2017
Open
European report calms common concerns
15 September 2017
Open
Europäer zahlen zu viel für Pillen
18 July 2017
Open
“É possível fazer os médicos portugueses prescreverem mais genéricos”
18 July 2017
Open
Jacek Glinka: “Biossimilares podem poupar ao SNS 120 milhões de euros”
18 July 2017
Open
Pharma expert: EU drug agency should be ‘easily’ accessible to all
18 July 2017
Open
Access to Medicines at Sustainable Price: Pharma Industry and Governments Transforming Challenges into Opportunities
23 March 2017
Open
Subscribe to our newsletter
Tweet
Tweet
Tweet
LinkedIn
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
